Pourmoussa A, Gardner DJ, Johnson MB, Wong AK, et al.
Annals of translational medicine. Date of publication 2016 Dec 1;volume 4(23):457.
1. Ann Transl Med. 2016 Dec;4(23):457. doi: 10.21037/atm.2016.12.44.
An update and review of cell-based wound dressings and their integration into
clinical practice.
Pourmoussa A(1), Gardner DJ(1), Johnson MB(1), Wong AK(1).
Author information:
(1)Division of Plastic and Reconstructive Surgery, Keck School of Medicine of
USC, Los Angeles, CA 90033, USA.
Chronic wounds affect over 4 million individuals and pose a significant burden to
the US healthcare system. Diabetes, venous stasis, radiation or paralysis are
common risk factors for chronic wounds. Unfortunately, the current standard of
care (SOC) has a high relapse rate and these wounds continue to adversely affect
patients' quality of life. Fortunately, advances in tissue engineering have
allowed for the development of cell-based wound dressings that promote wound
healing by improving cell migration and differentiation. As the available options
continue to increase in quantity and quality, physicians should have a
user-friendly guide to reference when deciding which dressing to use. The
objective of this review is to identify the currently available biologic
dressings, describe their indications, and provide a framework for integration
into clinical practice. This review included 53 studies consisting of prospective
and retrospective cohorts as well as several randomized control trials. Three
general categories of cell-based biologic dressings were identified and nine
brands were included. Cell-based biologic dressings have shown efficacy in a
broad range of scenarios, and studies examining their efficacy have improved our
understanding of the pathophysiology of chronic wounds. Amniotic and placental
membranes have the widest scope and can be used to treat all subtypes of chronic
wounds. Human skin allografts and bioengineered skin substitutes can be used for
chronic ulcers but generally require a vascularized wound bed. Autologous
platelet rich plasma (PRP) has shown promise in venous stasis ulcers and
decubitus ulcers that have failed conventional treatment. Overall, more research
is necessary to determine if these novel therapeutic options will change the
current SOC, but current studies demonstrate encouraging results in the treatment
of chronic wounds.
DOI: 10.21037/atm.2016.12.44
PMCID: PMC5220025
PMID: 28090513
Conflict of interest statement: The authors have no conflicts of interest to
declare.
